Beyond taxanes, XIAP has been shown to confer resistance to Doxorubicin in breast cancer (Delbue et al., 2020), and to cisplatin in colon, ovarian, lung, and pancreatic cancers (Xiong et al., 2017; Xu et al., 2017; Ma et al., 2009; Lopes et al., 2007). Here, XIAP is linked to pancreatic neoplasm.